Pfiz­er cel­e­brates ac­cel­er­at­ed win for po­ten­tial mul­ti­ple myelo­ma block­buster

Pfiz­er has se­cured an ac­cel­er­at­ed ap­proval for El­rex­fio, a po­ten­tial mul­ti­ple myelo­ma block­buster that Pfiz­er ex­pects could be­come a “multi­bil­lion-dol­lar fran­chise.”

El­rex­fio, al­so known as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER